7.00Open6.00Pre Close2 Volume118 Open Interest5.00Strike Price1.40KTurnover224.73%IV-7.98%PremiumDec 20, 2024Expiry Date8.04Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9832Delta0.0062Gamma1.61Leverage Ratio-0.0076Theta0.0025Rho1.58Eff Leverage0.0012Vega
Arcutis Biotherapeutics Stock Discussion
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
Long-term! 😜
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types | ARQT Stock News
No comment yet